BBT-401 is under clinical development by Bridge Biotherapeutics and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BBT-401’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BBT-401 is under development for the treatment of multiple sclerosis, ulcerative colitis and age related macular degeneration. It is administered through oral and rectal route. The drug candidate acts by targeting pellino-1.
Bridge Biotherapeutics overview
Bridge Biotherapeutics is a biotechnology company that develops novel therapeutics and unmet medical needs in conditions such as ulcerative colitis, fibrotic diseases and cancers. The company product pipeline incudes BBT-401, BBT-877 and BBT-176. Its other products comprise BBT-301, BBT-301, BBT-209, BBT-207 and BBT-401. Bridge Biotherapeutics also carries out the research and development and innovation of new drugs. The company operates in the US and South Korea. Bridge Biotherapeutics is headquartered in Seongnam, South Korea.
For a complete picture of BBT-401’s drug-specific PTSR and LoA scores, buy the report here.